Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Pfizer’s Oral JAK Trial Meets RA Endpoint | Contract Pharma

What are you searching for?

Sign in

Pfizer’s Oral JAK Trial Meets RA Endpoint

Pfizer achieved positive results from the ORAL Scan Phase III study of tofacitinib, an investigational oral JAK inhibitor, in patients with moderate-to-severe active rheumatoid arthritis (RA) who had an inadequate response to methotrexate (MTX).

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Pfizer achieved positive results from the ORAL Scan Phase III study of tofacitinib, an investigational oral JAK inhibitor, in patients with moderate-to-severe active rheumatoid arthritis (RA) who had an inadequate response to methotrexate (MTX). Patients were randomized to receive tofacitinib 5 or 10 mg BID or placebo added to background MTX.

The study met all primary endpoints at the 10 mg BID dose, showing statistically significant changes versus placebo in reducing signs and symptoms of RA, reducing the progression of structural damage at six months, improving physical function at three months, and in reaching DAS28-4 (ESR) <2.6 at six months.

For the 5 mg BID dose, the study demonstrated statistically significant improvements versus placebo in at six months, but the difference from placebo in mTSS did not reach statistical significance at six months.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters